Journal of Clinical Oncology, Vol 16, 3439-3460, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

R Fossati, C Confalonieri, V Torri, E Ghislandi, A Penna, V Pistotti, A Tinazzi and A Liberati
Laboratory of Clinical Research in Oncology, Italian Cochrane Centre, Mario Negri Institute for Pharmacologic Research, Milan. fossati@irfmn.mnegri.it

PURPOSE: A systematic review of randomized clinical trials (RCTs) was undertaken to assess the effectiveness of medical treatment for metastatic breast cancer. METHODS: RCTs published between 1975 and 1997 have been classified according to 12 therapeutic comparisons: (1) polychemotherapy (PCHT) agents versus single agent; (2) PCHT regimens with anthracycline versus PCHT without anthracycline; (3) other PCHT versus cyclophosphamide, methotrexate, and fluorouracil (CMF); (4) chemotherapy (CHT) with epirubicin versus CHT with doxorubicin; (5) CHT versus same CHT delivered with less intensive schedules; (6) other endocrine therapy (OET) versus tamoxifen; (7) OET plus tamoxifen versus tamoxifen alone; (8) OET versus medroxyprogesterone; (9) OET versus aromatase inhibitors; (10) OET versus megestrol; (11) endocrine therapy (ET) versus same ET at lower doses; and (12) CHT plus ET versus CHT. Tumor response rates, mortality hazards ratio (HR) and frequency of severe side effects were the outcome measures. RESULTS: A total of 189 eligible trials (31,510 patients) were identified. All provided response rates and 133 (70%) data or survival curves needed for calculation of the HR. In eight of 12 comparisons, statistically significant differences for response emerged (1, 2, 3, 5, 7, 8, 11, 12); all but no. 8 favored the first term of the comparison. Overall survival analysis showed better results of (a) PCHT versus single-agent CHT (HR=0.82; 95% confidence interval [CI], 0.75 to 0.90); (b) CHT with doxorubicin versus CHT with epirubicin (HR=1.13; 95% CI, 1.00 to 1.27); (c) CHT versus the same CHT delivered with less intensive schedules (HR=0.90; 95% CI, 0.83 to 0.97); (d) ET versus the same ET at lower doses (HR=0.86; 95% CI, 0.77 to 0.97). Quality of life was measured in only 2,995 of 31,510 patients (9.5%). CONCLUSION: Despite some evidence of effectiveness of specific regimens, the relevance of these findings is limited by the modest survival benefit and the lack of evaluation of the quality-of-life impact of these treatments.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Robson and S. Verma Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Oncologist, October 1, 2009; 14(10): 950 - 958. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Oncologist, October 1, 2009; 14(10): 959 - 962. [Full Text] [PDF]

				F. Cardoso, P. L. Bedard, E. P. Winer, O. Pagani, E. Senkus-Konefka, L. J. Fallowfield, S. Kyriakides, A. Costa, T. Cufer, K. S. Albain, et al. International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy J Natl Cancer Inst, September 2, 2009; 101(17): 1174 - 1181. [Abstract] [Full Text] [PDF]

				A. POLYZOS, H. GOGAS, C. MARKOPOULOS, N. TSAVARIS, O. PAPADOPOULOS, K. POLYZOS, and A. GIANNOPOULOS Salvage Chemotherapy with Oxaliplatin and Capecitabine for Breast Cancer Patients Pretreated with Anthracyclines and Taxanes Anticancer Res, July 1, 2009; 29(7): 2851 - 2856. [Abstract] [Full Text] [PDF]

				C. de la Fouchardiere, R. Largillier, Y. Goubely, A.-C. Hardy-Bessard, B. Slama, J. Cretin, H. Orfeuvre, D. Paraiso, T. Bachelot, and E. Pujade-Lauraine Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE Ann. Onc., June 25, 2009; (2009) mdp231v1. [Abstract] [Full Text] [PDF]

				S. Staal, M. J. O'Connell, and C. J. Allegra The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss or Bust? J. Clin. Oncol., April 1, 2009; 27(10): 1545 - 1548. [Full Text] [PDF]

				D. Mauri, N. P. Polyzos, G. Salanti, N. Pavlidis, and J. P. A. Ioannidis Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer J Natl Cancer Inst, December 17, 2008; 100(24): 1780 - 1791. [Abstract] [Full Text] [PDF]

				P. L. Bedard and M. J. Piccart-Gebhart Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math! J Natl Cancer Inst, December 17, 2008; 100(24): 1745 - 1747. [Full Text] [PDF]

				X. Pivot, P. Koralewski, J. L. Hidalgo, A. Chan, A. Goncalves, G. Schwartsmann, S. Assadourian, and J. P. Lotz A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann. Onc., September 1, 2008; 19(9): 1547 - 1552. [Abstract] [Full Text] [PDF]

				E. Mrozek, J. Kolesar, D. Young, J. Allen, M. Villalona-Calero, and C. L. Shapiro Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC) Ann. Onc., August 1, 2008; 19(8): 1417 - 1422. [Abstract] [Full Text] [PDF]

				T. Li, Y.-H. Ling, I. D. Goldman, and R. Perez-Soler Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells Clin. Cancer Res., June 1, 2007; 13(11): 3413 - 3422. [Abstract] [Full Text] [PDF]

				N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy Ann. Onc., April 1, 2007; 18(4): 694 - 700. [Abstract] [Full Text] [PDF]

				D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]

				F. Vigna-Taglianti, P. Vineis, A. Liberati, and F. Faggiano Quality of systematic reviews used in guidelines for oncology practice Ann. Onc., April 1, 2006; 17(4): 691 - 701. [Abstract] [Full Text] [PDF]

				C. A. Novosad, P. J. Bergman, M. G. O'Brien, J. A. McKnight, S. C. Charney, K. A. Selting, J. C. Graham, S. S. Correa, M. P. Rosenberg, and T. L. Gieger Retrospective Evaluation of Adjunctive Doxorubicin for the Treatment of Feline Mammary Gland Adenocarcinoma: 67 Cases J. Am. Anim. Hosp. Assoc., March 1, 2006; 42(2): 110 - 120. [Abstract] [Full Text] [PDF]

				R. E. Langley, J. Carmichael, A. L. Jones, D. A. Cameron, W. Qian, B. Uscinska, A. Howell, and M. Parmar Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01 J. Clin. Oncol., November 20, 2005; 23(33): 8322 - 8330. [Abstract] [Full Text] [PDF]

				M. Bontenbal, G.-J. Creemers, H. J. Braun, A. C. de Boer, J. Th. Janssen, R. B. Leys, J. B. Ruit, S. H. Goey, P. C. van der Velden, L. G. Kerkhofs, et al. Phase II to III Study Comparing Doxorubicin and Docetaxel With Fluorouracil, Doxorubicin, and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre J. Clin. Oncol., October 1, 2005; 23(28): 7081 - 7088. [Abstract] [Full Text] [PDF]

				J. O'Shaughnessy Extending Survival with Chemotherapy in Metastatic Breast Cancer Oncologist, October 1, 2005; 10(suppl_3): 20 - 29. [Abstract] [Full Text] [PDF]

				M. Tabuchi, H. To, H. Sakaguchi, N. Goto, A. Takeuchi, S. Higuchi, and S. Ohdo Therapeutic Index by Combination of Adriamycin and Docetaxel Depends on Dosing Time in Mice Cancer Res., September 15, 2005; 65(18): 8448 - 8454. [Abstract] [Full Text] [PDF]

				P. Bruzzi, L. Del Mastro, M. P. Sormani, L. Bastholt, M. Danova, C. Focan, G. Fountzilas, J. Paul, R. Rosso, and M. Venturini Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients J. Clin. Oncol., August 1, 2005; 23(22): 5117 - 5125. [Abstract] [Full Text] [PDF]

				A Bottini, A Berruti, M P Brizzi, A Bersiga, D Generali, G Allevi, S Aguggini, G Bolsi, S Bonardi, B Tondelli, et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial Endocr. Relat. Cancer, June 1, 2005; 12(2): 383 - 392. [Abstract] [Full Text] [PDF]

				E. Bajetta, G. Procopio, L. Celio, L. Gattinoni, S. Della Torre, L. Mariani, L. Catena, R. Ricotta, R. Longarini, N. Zilembo, et al. Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women J. Clin. Oncol., April 1, 2005; 23(10): 2155 - 2161. [Abstract] [Full Text] [PDF]

				A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]

				C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic, M. Welnicka-Jaskiewicz, C. Wiltschke, Z. Kahan, M. Grgic, V. Tzekova, M. Inbar, J. Cervek, et al. Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial J. Clin. Oncol., March 1, 2005; 23(7): 1401 - 1408. [Abstract] [Full Text] [PDF]

				M. Sandstrom, H. Lindman, P. Nygren, E. Lidbrink, J. Bergh, and M.O. Karlsson Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients J. Clin. Oncol., January 20, 2005; 23(3): 413 - 421. [Abstract] [Full Text] [PDF]

				C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]

				M. H. Kershaw, J. T. Jackson, N. M. Haynes, M. W. L. Teng, M. Moeller, Y. Hayakawa, S. E. Street, R. Cameron, J. E. Tanner, J. A. Trapani, et al. Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer J. Immunol., August 1, 2004; 173(3): 2143 - 2150. [Abstract] [Full Text] [PDF]

				B. Ejlertsen, H. T. Mouridsen, S. T. Langkjer, J. Andersen, J. Sjostrom, and M. Kjaer Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403) J. Clin. Oncol., June 15, 2004; 22(12): 2313 - 2320. [Abstract] [Full Text] [PDF]

				M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, et al. Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 759 - 769. [Abstract] [Full Text] [PDF]

				L. Reyno, L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, V. Gorbunova, A. Garin, J. Jassem, et al. Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19 J. Clin. Oncol., January 15, 2004; 22(2): 269 - 276. [Abstract] [Full Text] [PDF]

				C. T. Chung and R. W. Carlson Goals and Objectives in the Management of Metastatic Breast Cancer Oncologist, December 1, 2003; 8(6): 514 - 520. [Abstract] [Full Text] [PDF]

				M. Martin, M. Spielmann, M. Namer, A. duBois, C. Unger, D. Dodwell, P. Vodvarka, M. Lind, H. Calvert, A. Casado, et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines Ann. Onc., August 1, 2003; 14(8): 1246 - 1252. [Abstract] [Full Text] [PDF]

				V. Valero and G. N. Hortobagyi Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer? J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962. [Full Text] [PDF]

				J.-M. Nabholtz, C. Falkson, D. Campos, J. Szanto, M. Martin, S. Chan, T. Pienkowski, J. Zaluski, T. Pinter, M. Krzakowski, et al. Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial J. Clin. Oncol., March 15, 2003; 21(6): 968 - 975. [Abstract] [Full Text] [PDF]

				A. D. Seidman Sequential Single-Agent Chemotherapy for Metastatic Breast Cancer: Therapeutic Nihilism or Realism? J. Clin. Oncol., February 15, 2003; 21(4): 577 - 579. [Full Text] [PDF]

				B. Overmoyer Combination Chemotherapy for Metastatic Breast Cancer: Reaching for the Cure J. Clin. Oncol., February 15, 2003; 21(4): 580 - 582. [Full Text] [PDF]

				G. W. Sledge, D. Neuberg, P. Bernardo, J. N. Ingle, S. Martino, E. K. Rowinsky, and W. C. Wood Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) J. Clin. Oncol., February 15, 2003; 21(4): 588 - 592. [Abstract] [Full Text] [PDF]

				J. O'Shaughnessy, C. Twelves, and M. Aapro Treatment for Anthracycline-Pretreated Metastatic Breast Cancer Oncologist, December 1, 2002; 7(90006): 4 - 12. [Abstract] [Full Text] [PDF]

				D. Miles, G. von Minckwitz, and A. D. Seidman Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer Oncologist, December 1, 2002; 7(90006): 13 - 19. [Abstract] [Full Text] [PDF]

				A. Berruti, R. Bitossi, G. Gorzegno, A. Bottini, P. Alquati, A. De Matteis, F. Nuzzo, G. Giardina, S. Danese, M. De Lena, et al. Time to Progression in Metastatic Breast Cancer Patients Treated With Epirubicin Is Not Improved by the Addition of Either Cisplatin or Lonidamine: Final Results of a Phase III Study With a Factorial Design J. Clin. Oncol., October 15, 2002; 20(20): 4150 - 4159. [Abstract] [Full Text] [PDF]

				M. Pawlicki, J. Rolski, J. Zaluski, P. Siedlecki, C. Ramlau, and P. Tomzak A Phase II Study of Intravenous Navelbine and Doxorubicin Combination in Previously Untreated Advanced Breast Carcinoma Oncologist, June 1, 2002; 7(3): 205 - 209. [Abstract] [Full Text] [PDF]

				G. V. Kornek, K. Haider, W. Kwasny, M. Raderer, B. Schull, T. Payrits, D. Depisch, E. Kovats, F. Lang, and W. Scheithauer Treatment of Advanced Breast Cancer with Docetaxel and Gemcitabine with and without Human Granulocyte Colony-stimulating Factor Clin. Cancer Res., May 1, 2002; 8(5): 1051 - 1056. [Abstract] [Full Text] [PDF]

				R. Fossati, C. Confalonieri, G. Apolone, S. Cavuto, and S. Garattini Does a drug do better when it is new? Ann. Onc., March 1, 2002; 13(3): 470 - 473. [Abstract] [Full Text] [PDF]

				F. Cardoso, A. Di Leo, C. Lohrisch, C. Bernard, F. Ferreira, and M. J. Piccart Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann. Onc., February 20, 2002; 13(2): 197 - 207. [Abstract] [Full Text] [PDF]

				G. N Hortobagyi Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79. [Abstract] [Full Text] [PDF]

				C. Sessa and O. Pagani Docetaxel and Epirubicin in Advanced Breast Cancer Oncologist, June 1, 2001; 6(2008): 13 - 16. [Abstract] [Full Text] [PDF]

				J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, Z. Mrsic-Krmpotic, J. Berzins, T. Nagykalnai, N. Wigler, J. Renard, et al. Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial J. Clin. Oncol., March 15, 2001; 19(6): 1707 - 1715. [Abstract] [Full Text] [PDF]

				D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 N. Engl. J. Med., March 15, 2001; 344(11): 783 - 792. [Abstract] [Full Text] [PDF]

				J. M. Nabholtz, J. R. Mackey, M. Smylie, A. Paterson, D. R. Noel, T. Al-Tweigeri, K. Tonkin, S. North, N. Azli, and A. Riva Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer J. Clin. Oncol., January 15, 2001; 19(2): 314 - 321. [Abstract] [Full Text] [PDF]

				J. M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, and M. von Euler Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial J. Clin. Oncol., November 15, 2000; 18(22): 3758 - 3767. [Abstract] [Full Text] [PDF]

				A. Berruti, P. Sperone, A. Bottini, G. Gorzegno, V. Lorusso, A. Brunelli, M. Botta, M. Tampellini, M. Donadio, S. Mancarella, et al. Phase II Study of Vinorelbine With Protracted Fluorouracil Infusion as a Second- or Third-Line Approach for Advanced Breast Cancer Patients Previously Treated With Anthracyclines J. Clin. Oncol., October 19, 2000; 18(19): 3370 - 3377. [Abstract] [Full Text] [PDF]

				S. Garattini and A. Liberati The risk of bias from omitted research BMJ, October 7, 2000; 321(7265): 845 - 846. [Full Text]

				J. G. M. Klijn, L. V. A. M. Beex, L. Mauriac, J. A. van Zijl, C. Veyret, J. Wildiers, J. Jassem, M. Piccart, J. Burghouts, D. Becquart, et al. Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study J Natl Cancer Inst, June 7, 2000; 92(11): 903 - 911. [Abstract] [Full Text] [PDF]

				G. Cocconi and R. F. C. C. A. Tinazzi Chemotherapy With and Without Anthracycline J. Clin. Oncol., March 13, 2000; 18(6): 1392 - 1393. [Full Text] [PDF]

				W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer Oncologist, February 1, 2000; 5(1): 1 - 13. [Abstract] [Full Text]

				Y. Fujiwara Current Status of Oral Anticancer Drugs in Japan J. Clin. Oncol., October 1, 1999; 17(10): 3362 - 3365. [Full Text] [PDF]

				J. F. Bishop, J. Dewar, G. C. Toner, J. Smith, M. H.N. Tattersall, I. N. Olver, S. Ackland, I. Kennedy, D. Goldstein, H. Gurney, et al. Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer J. Clin. Oncol., August 1, 1999; 17(8): 2355 - 2355. [Abstract] [Full Text] [PDF]

				M. Buyse, R. W. Carlson, P. Piedbois, R. Fossati, C. Confalonieri, V. Torri, and A. Liberati Meta-Analyses of Published Results Are Unreliable J. Clin. Oncol., May 1, 1999; 17(5): 1644 - 1644. [Full Text] [PDF]